
ARTHROPLASTY
Rivaroxaban is an adequate treatment for thromboprophylaxis after total knee arthroplasty
This report has been verified
by one or more authors of the
original publication.
Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4
3148 patients who underwent total knee arthroplasty (TKA) were randomized to thromboprophylaxis using either orally administer rivaroxaban or subcutaneous injection of enoxaparin. This study assessed the efficacy of thromboprophylaxis treatment with rivaroxaban and assessed its non-inferiority to enoxaparin. The results of this study indicated that rivaroxaban was superior in comparison to enoxaparin for the use in patients undergoing total knee arthroplasty.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in


Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now